# Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells

> **NCT00078520** · PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 9 (actual)

## Conditions studied

- Leukemia
- Leukemia, B-Cell, Chronic

## Interventions

- **BIOLOGICAL:** Dose Level 1
- **BIOLOGICAL:** Dose Level 2
- **BIOLOGICAL:** Dose Level 2- Fixed Dose

## Key facts

- **NCT ID:** NCT00078520
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-01-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00078520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00078520, "Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00078520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*